Pacira BioSciences (PCRX) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Tyra Biosciences (TYRA) over the past year, gaining 57.5% versus a gain of 46.5%. Over five years, TYRA leads with a +22.2% price change compared with -31.7% for PCRX. Pacira BioSciences is the larger company by market cap ($1.45 billion vs $1.37 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PCRX | TYRA |
|---|---|---|
| Share price | $36.31 | $19.94 |
| Market cap | $1.45B | $1.37B |
| 1-day change | -0.22% | -0.15% |
| YTD return | +40.30% | -24.04% |
| 1-year return | +57.46% | +46.52% |
| 5-year return | -31.75% | +22.22% |
| P/E ratio (TTM) | 103.74 | — |
| Forward P/E | 10.50 | — |
| EPS (TTM) | $0.35 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $726.41M | — |
| Revenue growth (YoY) | +3.63% | — |
| Net income (latest FY) | $7.03M | — |
| Gross margin | 79.39% | — |
| Operating margin | 2.64% | — |
| Net margin | 0.97% | — |
| 52-week high | $36.46 | $40.65 |
| 52-week low | $18.80 | $13.29 |
| Distance from 52-week high | -0.41% | -50.95% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -17.08% | +137.96% |
| Average volume | 1.03M | 859.95K |
| Shares outstanding | 39.91M | 68.76M |
| Employees | 825 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCRX has outperformed TYRA by 10.9 percentage points over the past year.
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
PCRX vs TYRA FAQ
Which is bigger, Pacira BioSciences or Tyra Biosciences?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $1.37B for Tyra Biosciences (TYRA).
Which stock has performed better over the past year, PCRX or TYRA?
PCRX returned +57.46% over the past 12 months, compared with +46.52% for TYRA (price return, excluding dividends). Past performance does not predict future results.
Are Pacira BioSciences and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.